PRTN3 and rheumatoid arthritis: In fact, the active rheumatoid inflammatory process may contribute to enhancing the CV burden risk of these patients.[2–4,8,9] Thus, the maintenance of clinical remission should be considered the pivotal goal for RA management.[38] Furthermore, a treat-to-target intervention, aiming at clinical remission, may also reduce the occurrence of cardiometabolic multimorbidity.[2,36] Additionally, the presence of cardiometabolic multimorbidity were associated with ACPA positivity and extra-articular disease manifestations.